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H I G H L I G H T S
• Macro-calcification in carotid lesions was assessed by CTA and microarrays.• Calcification was linked to a transcriptional profile typical for stable plaques.• PRG4 was enriched in calcified ECM and localized to activated macrophages and SMCs.• Assessment of calcification may aid evaluation of plaque phenotype and stroke risk.








A B S T R A C T
Background and aims: Unstable carotid atherosclerosis causes stroke, but methods to identify patients and lesions at
risk are lacking. We recently found enrichment of genes associated with calcification in carotid plaques from asymp-
tomatic patients. Here, we hypothesized that calcification represents a stabilising feature of plaques and investigated
howmacro-calcification, as estimated by computed tomography (CT), correlates with gene expression profiles in lesions.
Methods: Plaque calcification was measured in pre-operative CT angiographies. Plaques were sorted into high- and low-
calcified, profiled with microarrays, followed by bioinformatic analyses. Immunohistochemistry and qPCR were per-
formed to evaluate the findings in plaques and arteries with medial calcification from chronic kidney disease patients.
Results: Smooth muscle cell (SMC) markers were upregulated in high-calcified plaques and calcified plaques
from symptomatic patients, whereas macrophage markers were downregulated. The most enriched processes in
high-calcified plaques were related to SMCs and extracellular matrix (ECM) organization, while inflammation,
lipid transport and chemokine signaling were repressed. These findings were confirmed in arteries with high
medial calcification. Proteoglycan 4 (PRG4) was identified as the most upregulated gene in association with
plaque calcification and found in the ECM, SMA+ and CD68+/TRAP + cells.
Conclusions: Macro-calcification in carotid lesions correlated with a transcriptional profile typical for stable
plaques, with altered SMC phenotype and ECM composition and repressed inflammation. PRG4, previously not
described in atherosclerosis, was enriched in the calcified ECM and localized to activated macrophages and
smooth muscle-like cells. This study strengthens the notion that assessment of calcification may aid evaluation of
plaque phenotype and stroke risk.
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Unstable atherosclerosis in the carotid bifurcation has been linked
to approximately 10–20% of all ischemic strokes [1]. It is difficult to
estimate precisely to what extent carotid plaques contribute to extra-
cranial atheroembolism as we lack imaging modalities capable of
identifying unstable lesions [2]. Today, risk assessment based on the
degree of luminal narrowing by stenosis yields moderate procedural
efficacy for stroke-preventive surgery (carotid endarterectomy, CEA) in
symptomatic patients and questionable efficacy for asymptomatic ones
[3]. New imaging modalities are therefore being developed to identify
high-risk lesions and improve stroke prevention. Understanding the
biological processes that underlie morphological plaque features re-
cognized by these modalities would strengthen their predictive power
in selection of patients for intervention [2].
Unstable atherosclerotic plaques are characterized by disruption of
the protective fibrous cap, endothelial erosions, enhanced inflamma-
tion, large lipid-rich necrotic cores and intraplaque haemorrhage, while
stable lesions typically contain more smooth muscle cells (SMCs) and
fibrous tissue [4]. In atherogenesis, contractile SMCs modulate into a
proliferative and synthetic phenotype that migrates from the media into
the intima, secrete extracellular matrix (ECM) components and build
the fibrous cap [5]. Within lesion, SMCs have been assigned broad
phenotypic plasticity [5–7] and reported to coexist in various inter-
mediate phenotypes. In a recent study, we have shown that SMCs in
carotid atherosclerosis downregulate classical and hitherto unknown
markers for cytoskeletal integrity as well as calcium (Ca) signaling (i.e.
ACTA2, MYH11, PDLIM7, SYNPO2, LMOD1, PLN) [8].
Calcification is a prominent feature of end-stage atherosclerosis, but
it is also typical for the artery media of patients with chronic kidney
disease (CKD) [9,10]. Vascular calcification can be influenced by al-
tered Ca and phosphate homeostasis, loss of mineralization inhibitors
and dysfunction of natural regulators in bone metabolism such as os-
teopontin, osteoprotegerin, matrix-gla protein, fetuin-A and receptor
activator of NF-κB. Whereas intimal calcification is coupled to plaque
inflammation and lipid deposition, medial calcification involves toxic
metabolite-induced vascular changes that promote osteogenic differ-
entiation and subsequent matrix mineralization. Clinically, medial
calcification leads to arterial stiffness and increased pulse pressure,
while the consequences of intimal calcification are less clear [11].
Moreover, intimal micro- and macro-calcification have been suggested
to influence plaque stability differently [12,13], however, the impact of
size, composition, and distribution of calcification in plaque vulner-
ability, remains unclear. Computerized tomography (CT) images calci-
fications in atherosclerosis [13] and scoring of coronary artery calcifi-
cation by CT (CAC score) has been implemented in prediction of
cardiovascular risk. High CAC score confers increased cardiovascular
risk [13], whereas carotid plaque calcifications seem to be associated
with reduced stroke risk [14,15].
We and others [16,17] recently confirmed that molecular pathways
related to calcification dominate in end-stage carotid plaques. While
osteolytic processes, suggesting reduced calcification, were prevalent in
plaques from symptomatic patients, plaques from patients on statin
therapy and asymptomatic ones were enriched in processes associated
with increased calcification [8]. To investigate this further, here we
focused on the transcriptome of calcified carotid plaques, by selecting
patients with different degrees of calcification as estimated by pre-
operative CT angiographies (CTA) and analysed global gene expression
profiles in corresponding CEA specimens using microarrays. We show
that high-calcified lesions were enriched in molecular processes asso-
ciated with SMC function, ECM organization and calcification, while
inflammation, lipid metabolism and chemokine signaling were re-
pressed.
2. Materials and methods
2.1. Human carotid atherosclerosis cohort
Patients undergoing surgery for high-grade (> 50% NASCET) [18]
carotid stenosis at the Department of Vascular Surgery, Karolinska
University Hospital, Stockholm, Sweden were consecutively enrolled in
the study and clinical data recorded on admission. Patients with high
vs. low calcified carotid lesions on CTA were selected for the study.
Symptoms (S) were defined as transitory ischemic attack (TIA), minor
stroke (MS) and amaurosis fugax (retinal TIA). Patients without quali-
fying symptoms within 3 months prior to surgery were categorised as
asymptomatic (AS) and indication for CEA based on results from the
Asymptomatic Carotid Surgery Trial (ACST) [19]. Carotid en-
darterectomies (carotid plaques, CP) were collected at surgery and re-
tained within the Biobank of Karolinska Endarterectomies (BiKE). The
study cohort demographics, details of sample collection and processing
and transcriptomic analyses by microarrays were as previously de-
scribed in details [8,20,21] and shown in Supplementary Tables I and II
Briefly, plaques were divided transversally at the most stenotic part; the
proximal half of the lesion was used for RNA preparation while the
distal half was immediately fixed in 4% formaldehyde for 48 h. Highly
calcified specimens planned for histological analyses, were first dec-
alcified in Modified Decalcification Solution (formic acid; Histolab,
Gothenburg, Sweden) for 5 days, and all specimens were dehydrated in
graded ethanol and embedded in paraffin.
All human samples were collected with informed consent from pa-
tients; studies were approved by the regional Ethical Committee and
follow the guidelines of the Declaration of Helsinki.
2.2. Computed tomography angiography (CTA) examination and image
analysis
Carotid CTA was performed as a pre-operative routine at the ad-
mitting hospital using site-specific image acquisition protocols (ex-
amination protocols in Supplementary Table III). CTA exams were
performed between March 2008 and October 2013, in 7 different CT-
labs at 5 hospitals, using 3 vendors and in total 4 different models. In
summary, CTA exams were performed with 100 or 120 kVp, variation
of CTDIvol16cm between 13.9 and 36.9mGy or CTDIvol32cm
7.9–28.3 mGy. Contrast injection rate and amount followed by a saline
chaser were at the discretion of the local hospitals. Briefly, a caudo-
cranial scanning direction was selected from the aortic arch to the
vertex, using intravenous contrast. An axial image reconstruction of
0.625mm (in 37 exams; 0.9 mm in two exams; and 1mm in one exam)
was obtained and transferred into a digital workstation for vascular CT-
scan image analysis using the Plaque Analysis application of the Ter-
aRecon software (iNtuition, TeraRecon, Foster City, CA, USA). A cen-
treline of flow was semi-automatically placed from the common to the
internal carotid artery. The area of the atherosclerotic plaque was
manually selected using the common carotid bifurcation as a reference
point. The outer and inner borders of the artery wall were automatically
defined, adjusted manually, the lumen was excluded from the analysis
and artery wall volumes automatically calculated within 5 different
levels of Hounsfield Units (HU) with standardised cut-offs (−150 HU to
0 HU; 1 HU to 129 HU; 130 HU to 199 HU; 200 HU to 299 HU; 300 HU
to 399 and 400 HU to 3000 HU). The analysis provided a semi-auto-
matically generated calcium volume of the carotid plaque, which was
analysed with a threshold of 400 Hounsfield Units (HU) for calcification
and a ratio was calculated (Vcalc/Vtot= calcification degree). The
measurements of CT images were done by the same observer (E. K.) and
blinded to histological and biochemical analysis. The measurements
were restricted to the most proximal half of the plaque with cutoff level
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at tightest stenosis, in order to correlate CTA to the corresponding
plaque microarray analysis.
2.3. Bioinformatic and statistical analyses
Transcriptomic dataset was pre-processed using Bioconductor soft-
ware. For the initial discovery, group analyses were performed by a
two-sided Student's t-test assuming non-equal deviation with correction
for multiple comparisons according to Bonferroni, as previously de-
scribed [8,21]. Subsequently, to confirm the most important results
presented in the study, a linear regression model was used with calci-
fication as the continuous variable. Graphs were generated using
GraphPad Prism 6. Discovery analyses of highly significantly dysregu-
lated genes were performed by comparing patients with the 10 most
highly calcified plaques (30–65%) vs. 10 least calcified ones (0–2%), as
well as 7 symptomatic vs. 7 asymptomatic patients from the high-cal-
cified group, while the whole cohort of 40 patients was used for vali-
dation of results. Following differential gene expression, gene set en-
richment analyses on Gene Ontology (GO) terms were performed using
several public softwares for comparison: GeneMania (www.genemania.
org), GOrilla (http://cbl-gorilla.cs.technion.ac.il) and ENRICHR
(http://amp.pharm.mssm.edu/Enrichr). Final data presented was from
GOrilla including filtering of overlapping GO categories was performed
using Revigo software (http://revigo.irb.hr). Functional data about the
genes was extracted using GeneCards (www.genecards.org) and
PubMed literature search. Pearson correlations were calculated to de-
termine the association between mRNA expression levels from micro-
arrays. Large-scale overall correlation analyses were conducted using
Morpheus software (http://software.broadinstitute.org/morpheus).
The minimal gene signature/combined panel predicted for separating
two groups of patients was analysed using the default settings of the
‘Marker prediction’ tool in the Morpheus software, Broad Institute and
based on the whole microarray dataset, taking into account differential
gene expression and 100 permutations for obtaining the prediction
accuracy. Principal components (PCA) analysis was performed using
ClustVis software (https://biit.cs.ut.ee/clustvis_large/). To enumerate
the relative abundance of cellular populations in the tissue composition,
we applied the mRNA deconvolution strategy to microarrays using the
Cibersort web software (https://cibersort.stanford.edu). In this ana-
lysis, immune cell populations were deconvoluted using a publicly
available expression file containing signature markers for 22 different
leukocyte subtypes [22]. Cell compartments localization data was
analysed using the SubCellBarCode software (http://subcellbarcode.
org) [23] and based on the differentially expressed genes between high
vs. low calcified plaques. In all analyses adjusted p < 0.05 was con-
sidered to indicate statistical significance.
Additional Material and Methods are described in Supplementary
Data.
3. Results
3.1. Study design and CTA classification of plaque calcification
Patients undergoing CEA (n= 40 totally) were enrolled in the study
by: i) assesment of the calcification grade in pre-operative CTA, ii)
matching concerning symptomatology, comorbidities, age, gender, and
iii) quality of RNA material extracted from plaques (Fig. 1A). Overall,
plaques were categorised into high-calcified (18–65% calcification;
Fig. 1. Study workflow.
(A) Carotid plaques (n= 40 patients) were classified into high- and low-calcified by pre-operative CTA and profiled by microarrays, followed with bioinformatic
analyses. Results were evaluated in an independent cohort of arteries (n=61) with medial calcification and by large-scale in situ technologies (tissue microarrays,
n = 109). (B) Representative CTA images of high- and low-calcified plaques, gross morphology and histology of calcification (dotted line) by Alizarin Red staining.
(C) Plaque calcification estimated by CTA or Alizarin red content positively associates with hsCRP and creatinine levels, but negatively with BMI. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this
article.)
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n=18 patients) and low-calcified (0–10%; n= 22; Fig. 1B), and global
gene expression in plaques was profiled by microarrays followed by
bioinformatic analyses. To increase significance for discovery of dys-
regulated genes in calcification, analyses were initially performed in
two well-separated groups of the 10 most calcified plaques (30–65%)
vs. the 10 least calcified ones (0–2%), while the whole cohort was used
in validation. In order to investigate the molecular profile of calcifica-
tion with respect to patient symptomatology, analyses were also made
within the high-calcified group of plaques comparing those from
symptomatic (n=7) vs. asymptomatic (n=7) patients. The most sig-
nificant findings from these analyses were then investigated an in-
dependent cohort of arteries with medial calcification (n=61,
Supplementary Table II). In addition, plaque calcification was esti-
mated histologically by Alizarin red staining of lesions and the most
significant findings were semi-quantitated using tissue microarrays
(TMAs; n=109 patients).
There were no significant differences between high and low calci-
fied patient groups with respect to general characteristics, symptoma-
tology, smoking or medical treatment (Supplementary Table I). Corre-
lation analysis between plaque calcification estimated by CTA or
histology and clinical parameters (Supplementary Table IV), showed
positive association only with plasma hs-CRP and creatinine, while
association was negative with BMI (Fig. 1C).
3.2. Calcification associates with enrichment of smooth muscle related
pathways and repression of inflammation
Global gene expression analysis comparing high vs. low calcified
plaques resulted in 3387 significantly differentially expressed probe-
sets, of which 1783 were upregulated and 1604 downregulated (of to-
tally 70526 microarray probesets, Bonferroni adjusted p < 0.05,
Supplementary Tables V and VI). There was a striking upregulation of
typical SMC contractility markers such as CNN1, ACTA2, MYOCD
(Fig. 2A) and even sensitive markers recently shown to be down-
regulated in carotid plaques in general (SYNPO2, LMOD1, PDLIM7,
MYH11, PLN, all p < 0.0001, Supplementary Table V) [21]. This was
accompanied by upregulation of ECM-related genes such as ELN, col-
lagens, integrins and proteoglycans (i.e. PRG4, CSPG4, HSPG2). In
contrast, markers of macrophages (CD68, MARCO, CD36), lipid turn-
over (LPL, APOC1, PLIN2, ALOX5), ECM degradation (MMP7, MMP8,
MMP9, MMP12, cathepsins) and chemokines (CCL18, CCL3, CCL4,
CXCR4, IL8, all p < 0.0001) were downregulated (Fig. 2B,
Supplementary Table VI). The data was validated in silico by micro-
arrays from the whole cohort of 40 patients comparing high vs. low
calcified groups, and additionally using the linear regression model
(Supplementary Fig. IA, Supplementary Table VII).
Gene set enrichment and pathway analyses on significantly
Fig. 2. SMC-related processes are induced in high-calcified plaques and inflammation is repressed.
(A) Microarray analysis comparing high vs. low calcified plaques showed upregulation of SMC contractility markers, and (B) downregulation of markers for mac-
rophages (CD68), lipids (LPL) and ECM degradation (MMP7). Plots show mean log2 with SD. (C) Pathway analyses confirmed induction of processes related to
calcification and SMC function in high-calcified plaques, and repression of inflammation, cholesterol metabolism response to cytokines. (D) Prediction modelling
revealed a panel signature of 20 genes (y-axis) separating high vs. low calcified plaques with 100% accuracy. All genes were significant in comparison between high
and low calcified plaques (p < 0.01). Clustering of patients into groups according to gene expression levels shown above the X-axis; red color refers to high and blue
to low gene expression. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (For interpretation of the references to color in this figure legend, the reader is
referred to the Web version of this article.)
E. Karlöf, et al. Atherosclerosis 288 (2019) 175–185
178
differentially expressed genes, confirmed induction of processes related
to Ca-signaling, but also to smooth muscle function (i.e. muscle con-
traction) in high calcified plaques (Fig. 2C, Supplementary Table VIII).
In particular, calcification processes, markers of chondrocytes
(COL2A1, COL1A1, ACAN, MMP13) and osteoblasts (IGF1R, BMP4,
SPARC, S100A4, SOST) were upregulated in high-calcified plaques and
strongly positively correlated to markers of contractile SMCs (MYH11,
ACTA2, LMOD1, SYNPO2), while markers of osteoclasts were down-
regulated (CSF1, OSCAR) (Supplementary Tables IX and X). Overall,
repression of processes associated with inflammation, ECM degrada-
tion, cholesterol metabolism, and response to cytokines was confirmed
in high-calcified plaques (Fig. 2C, Supplementary Table VIII). Among
the most repressed pathways were e.g. response to TNF, IL1, IFNg,
phagocytosis and chemokine-mediated signaling.
In addition, we also studied the enrichment of subcellular com-
partments in plaques by comparing the predicted localization of dif-
ferentially expressed genes from high vs. low calcified plaques in this
study with those previously published in plaques from asymptomatic vs.
symptomatic patients (Supplementary Fig. II) [8]. Here we also found
that cytoskeletal localization was strikingly enriched in high calcified
plaques, while nuclear and mitochondrial gene expression on the other
hand seemed to be repressed, especially in comparison to plaques from
asymptomatic patients.
However, despite substantial gene expression differences, principal
components analysis for classification of patients in high vs. low calci-
fied groups based on the global transcriptomic profiles could explain
about 24% of the variance between groups (Supplementary Fig. III). By
prediction modelling, we revealed a combined signature panel of 20
genes which was capable of considerably improving this separation and
explaining up to 65% of the variance between groups (Fig. 2D). This
panel comprised: genes involved in vesicle transport (SYT15, CHMP2B);
TGFBR3 that inhibits TGFB1 signaling; bone resorption inhibitor
(RAMP3); protease inhibitors (TIMP4, HTRA4); and ion channels
(KCNJ5, TRPM2).
Together, these bioinformatic analyses indicated that macro-calci-
fication is not only a prominent morphological feature, but also asso-
ciated with a distinct molecular phenotype of late-stage plaques and
correlated with induction of processes traditionally linked with plaque-
stabilization, while classical atherogenic and destabilizing processes
were repressed.
3.3. Stabilising processes are also induced in calcified plaques from
symptomatic patients
Next, we examined the molecular signature of calcified plaques
particularly in relation to patient symptoms (Fig. 3A). Global gene ex-
pression analysis comparing plaques from S vs. AS high-calcified pa-
tients, resulted in totally 1900 significantly differentially expressed
Fig. 3. Inflammation and tissue degradation are repressed in calcified plaques from symptomatic patients.
(A) From the whole cohort of 40 patients, association of calcification with patient symptomatology was assessed in a selected cohort of high-calcified plaques, where
no significant differences were observed for other clinical parameters (n = 7 symptomatic vs. 7 asymptomatic patients). (B) Pathway analyses showed an expected
induction of processes related to intra-plaque haemorrhage in high-calcified plaques from symptomatic patients, but also enrichment of extracellular matrix (ECM)
and tissue organization. Inflammation and tissue-degradative processes were suppressed. (C) Microarray analysis showed an upregulation of SMC contractility
markers, and downregulation of markers for macrophages, lipids and ECM degradation. Plots show mean log2 with SD. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001.
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probesets (Bonferroni adjusted p < 0.05, Supplementary Tables XI and
XII). In S patients, gene set enrichment and pathway analyses confirmed
induction of processes related to intraplaque haemorhhage (i.e. fibrin
clot formation, iron uptake and platelet degranulation), but also
pointed to an enrichment of ECM organization via elastin and pro-
teoglycans. Tissue degradation and immune-cell activation were re-
pressed in high calcified plaques from S patients (Fig. 3B,
Supplementary Table XIII). Here, we also noted an upregulation of both
classical and novel SMC contractility markers [21], while markers of
macrophages (CD163), lipid metabolism (PLIN2, PLA2G7) and ECM
degradation (MMP9, MMP12) were downregulated (Fig. 3C,
Supplementary Tables XI and XII). Additional gene expression data
from this subset of patients for relevant markers is shown in
Supplementary Fig. IB. This analysis revealed that macro-calcification
consistently associates with features typical for plaque stabilization on
molecular level, even in patients that have suffered symtoms.
Enhanced expression of SMC markers, elastin and collagen is
common for intimal and medial calcification.
In order to investigate further the observed enrichment of SMC
contractility and ECM genes in association to plaque calcification, we
combined gene and tissue microarrays (TMA) for assessment of both
mRNA and proteins (Fig. 4A). ACTA2 was found to be upregulated in
high vs. low calcified plaques and strongly positively correlated with
expression of ELN and collagen by gene microarrays. On protein level,
TMAs confirmed strong positive association between plaque calcifica-
tion and collagen content as well as between SMA and elastin/collagen
content. Histological stainings revealed a repression of sensitive SMC
markers (i.e. PDLIM7, LMOD1) in low calcified plaques [21], as well as
ECM proteins (elastin, collagen, proteoglycans), but in high-calcified
plaques all were abundant (Fig. 4B).
We next examined if the observed pattern of smooth muscle con-
tractility and ECM genes also appeared in epigastric arteries with
medial calcification from CKD patients (Supplementary Fig. IV).
Quantitatively, by low-density qPCR arrays (LDA), a significant in-
crease in ACTA2 could be shown in association with calcification as
well as a strongly positive correlation with expression of elastin and
collagen (Supplementary Fig. IVA). In arteries with medial calcification
we could also validate the positive correlation between ACTA2 and
calcification markers previously observed in high-calcified plaques
(Pearson r [ACTA2/BGLAP]= 0.44, p=0.004; Pearson r [ACTA2/
BMP2]= 0.47, p < 0.0001). Histological staining demonstrated a si-
milar expression pattern of SMC markers as observed in calcified pla-
ques along with increased staining for elastin and collagen in the media
(Supplementary Fig. IVB).
Active inflammation driven by CD4+ cells, macrophages and mast
cells is repressed in high calcified plaques.
The observed downregulation of inflammation markers and path-
ways in high calcified plaques was investigated further using the mi-
croarray deconvolution method, based on the expression of signature
markers for 22 different leukocyte subtypes [22]. Our analyses con-
firmed that macrophages and CD4+ cells are the most abundant im-
mune cells in plaques generally (Fig. 5). Interestingly, low calcified
plaques contained relatively more activated immune cells such as mast
cells, NK cells, M0 macrophages and memory B cells, while high cal-
cified plaques contained more resting CD4+ and mast cells (Fig. 5A).
Surprisingly, this pattern persists even when patients in this cohort are
stratified according to symptoms, where the symptomatic but highly
calcified ones appear to have less activated mast cells and M0 macro-
phages, and more protective M2 macrophages (Fig. 5B). Im-
munohistochemical analysis confirmed the basic differences in markers
of active inflammation (i.e. macrophages CD68, activated mast cells
Tryptase) between low and high calcified plaques (Fig. 5C).
Thus, using a combination of advanced bioinformatic and histolo-
gical analyses, our data shows the induction of SMC- and ECM-related
processes and dampened inflammation in high calcified lesions, even in
those from symptomatic patients.
3.4. PRG4 is the top upregulated gene in high-calcified plaques
Numerous genes previously not associated with atherosclerosis were
found to be highly upregulated in high vs. low calcified plaques (i.e.
Nephronectin; Dermatopontin; Intelectin 1; Supplementary Table V).
Proteoglycan 4 (PRG4) emerged as the most significantly upregulated
gene in this comparison (9x fold change, adj p < 0.0001)
(Supplementary Table V, Fig. 6A). This finding could be validated by
microarrays in the whole cohort of 40 patients (Fig. 6B), and the same
trend was confirmed by quantitative PCR in a small number of addi-
tional non-overlapping patients (Fig. 6C). In high calcified plaques from
symptomatic vs. asymptomatic patients PRG4 was still highly upregu-
lated (5.8x fold change, adj p < 0.0001) (Fig. 6D, Supplementary
Table XI), and was therefore selected for a more detailed investigation.
To delineate the functional associations of PRG4, expression of this
gene was first correlated with the whole transcriptome in calcified
plaques (Supplementary Fig. VA), which highlighted i.e. transcription
factors NFE2L2, MRPL and SMDT1 that mediate Ca uptake in mi-
tochondria, Ca-binding S100P and the phagocytic receptor VSIG4 (all
Pearson r > 0.8) as the top correlated genes. Overall, PRG4 associated
with processes such as response to inorganic ion and chemokine sig-
naling, but most enrichment was found for hematopoietic progenitor
cell differentiation and inhibition of vascular SMC migration (Fig. 6E).
Similarly, correlations of PRG4 with markers of major cell types in
calcified plaques were assessed (Supplementary Fig. VB), showing a
weaker but positive association to both inflammatory and smooth
muscle cells, and strongly positive with bone metabolism and osteo-
lysis/osteoclasts (i.e. IBSP, BMP2, SOX9, RUNX2, OSCAR, TNFRSF11A,
ACP5/TRAP), osteoarthritis markers (TNFAIP6), and also with some
markers of inflammation inhibition (CTLA4).
On protein level, immunostaining (Fig. 6F, Supplementary Fig. VI)
demonstrated that PRG4 was abundant in carotid plaques where it was
localized mainly to the ECM in osteopontin (OPN) and osteocalcin
(OCN) positive areas. In low calcified lesions, PRG4 was found in
SMA + regions both intra- and extra-celullarly, while in high-calcified
plaques it was observed in CD68+/TRAP + cells surrounding the
macro-calcification nodules. However, abundant signal for PRG4 could
not be observed in ECM of arteries with high medial calcification and
instead only sporadic expression was noted (Supplementary Fig. VII).
4. Discussion
Here we investigated gene expression signatures and molecular
pathways in high or low calcified carotid lesions as estimated by pre-
operative CTA. Our results demonstrated: i) that macro-calcification
associates with processes typically related to a more stable plaque
phenotype; ii) upregulated expression of SMC differentiation markers is
concurrent with repression of inflammation and increased expression of
calcification markers and ECM molecules in carotid plaques and in
arteries with medial calcification; iii) PRG4, previously not described in
atherosclerosis, is the most upregulated gene in high-calcified carotid
plaques.
CTA estimation of carotid plaque calcification correlated to distinct
gene expression profiles, even when patient symptomatology was taken
into account. We cannot exclude that the latter findings at least partly
could be explained by severe plaque heterogeneity (see limitations).
Overall, biological processes related to SMC function and cell cytoske-
leton were induced in high-calcified lesions, while processes typically
associated with unstable lesions such as inflammation, ECM degrada-
tion, and cholesterol metabolism were repressed. By prediction mod-
elling, a panel of 20 genes was enough to separate high from low cal-
cified plaques with 100% accuracy. For comparison, we previously
reported that a panel of 30 genes could discriminate plaques from S vs.
AS patients with 78% accuracy [8]. Thus, our findings suggested that
CTA can provide additional information on plaque phenotype, as op-
posed to comparisons based solely on patient phenotype, and support
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previous proposals that CTA estimation of calcification may aid pre-
diction of stroke risk in patients with carotid disease [14].
This study was restricted to estimation of macro-calcification, which
has previously been associated with more stable coronary lesions [24].
In contrast, micro-calcifications have been linked to unstable lesions in
patients [25] and plaque inflammation in ApoE−/− mice [12]. Of the
clinical parameters tested in our study, only creatinine and CRP posi-
tively correlated with calcification, whereas correlation with BMI was
negative. The association between creatinine and calcification was ex-
pected as impaired renal function has an established role in progression
Fig. 4. Validation of SMC related changes in high-calcified plaques.
(A) By gene (left) and tissue (right) microarrays, increase in ACTA2 was found in high-calcified plaques. ACTA2 upregulation positively correlated with mRNA
expression of elastin and collagen. Tissue microarrays (TMAs) validated the positive association between calcification and collagen content, and between SMA and
elastin/collagen content (lower panels) on protein level. (B) Stainings showed abundant signal for SMC markers (PDLIM7, LMOD1), elastin (Weigert, dark purple),
collagen (Masson trichrome, dark blue) and proteoglycans (Movat pentachrome, light green) in high-compared to low-calcified plaques (Alizarin Red). Images show
2× magnification, enlarged images show 40×. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (For interpretation of the references to color in this figure
legend, the reader is referred to the Web version of this article.)
E. Karlöf, et al. Atherosclerosis 288 (2019) 175–185
181
of vascular calcification [26]. In support of our findings, BMI has pre-
viously been coupled to echolucent and low-calcified plaques by carotid
ultrasound in diabetes patients [27]. While association between CRP
and vascular calcification in CKD [28] has been shown, and CRP seems
related to progression of carotid stenosis [29], a positive association to
carotid calcification has not been shown before. Possibly, the moderate
association found in our study reflects residual long-term systemic in-
flammation or increased vascular senescence in end-stage athero-
sclerosis, similarly as previously shown in CKD [9].
With respect to individual genes, expression of SMC markers was
significantly elevated in high-calcified lesions, and strongly correlated
to calcification genes. This finding shows that calcification in end-stage
atherosclerosis can be present together with SMCs expressing con-
tractility markers associated with a more differentiated phenotype. In
atherogenesis, SMCs have been shown to undergo transition into cells of
other lineages and calcification has been associated with
transdifferentiation of SMCs into chondro- and osteoblast-like cells
[30]. We and others have shown that SMC reacquire gene expression
features typical for quiescent, differentiated phenotype during recovery
after vascular injury [21] and our findings here imply that SMCs may
also maintain or reestablish a differentiated SMC transcriptome in the
presence of calcification, as opposed to a terminal transition into an
osteo-chondrogenic phenotype. In support of these findings, calcifying
SMCs in vitro were recently demonstrated to induce osteogenic path-
ways while maintaining the ability to express typical SMC contractile
markers [7]. Moreover, by comparing high-calcified plaques and ar-
teries with medial calcification, a process largely devoid of features
associated with atherosclerosis [10], a similar sustained expression of
SMC markers was observed. In both intimal and medial calcification,
elastin and collagen levels, and in plaques also HSPG2 (perlecan) levels,
were strongly associated with expression of SMC contractility markers.
We have previously shown that ECM can regulate the phenotypic state
Fig. 5. Validation of inflammation related changes in calcified plaques.
(A) Deconvolution analysis based on microarrays from all n= 40 patients shows that low calcified plaques contain relatively more activated inflammatory cells (mast
cells, NK cells, M0 macrophages and memory B cells), while high calcified plaques have a higher fraction of resting CD4+ cells and mast cells. (B) A similar pattern
persists in high calcified plaques stratified according to symptoms, where differences between lesions from asymptomatic and symptomatic patients are dominated by
relative contributions of activated vs. resting mast cells and M0 vs. M2 macrophages. (C) Histological analysis illustrates the basic differences in markers of active
inflammation (CD68, Tryptase) between low and high calcified plaques. Alizarin Red shows calcification. Images show 2x (Alizarin Red), 4x (CD68 and Tryptase),
and enlarged images 40× magnification. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (For interpretation of the references to color in this figure
legend, the reader is referred to the Web version of this article.)
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of SMCs and that basement membrane components, such as perlecan,
promote SMC quiescence and differentiation [31]. Although generally
reduced in carotid atherosclerosis [32], the upregulation of HSPG2 and
the collagen- and elastin rich ECM observed in high-calcified plaques,
suggests a pericellular environment that favors a more differentiated
SMC phenotype [33,34]. Enrichment of these ECM components also
indicated a more stable connective tissue, further supporting the asso-
ciation between plaque calcification and stability. Similarly, in vitro
macro-calcification has been shown to increase cellular resistance to
fluid sheer stress through enhanced cell-matrix interactions [35] and
SMCs have a well-documented capacity to respond to physical forces
and mechanical stretch [36]. Previous studies have already demon-
strated elevated serum-titers of degraded elastin in patients with
symptomatic carotid stenosis [37], increased stroke risk associated with
low carotid plaque elastin content [38,39], and reduced elastin ex-
pression in plaques from S vs. AS patients [40].
Atherosclerosis is a chronic inflammatory disease where the con-
tribution of various leukocyte subtypes has been extensively studied in
the human context. Here, we were able to show that a dampening in
active inflammation ongoing in the high-calcified lesions happens
concurrently with increased stability via SMC- and ECM-related pro-
cesses, even in lesions from symptomatic patients. These effects were
mostly driven by differences in the relative fractions of active vs. resting
mast cells, M0 vs. M2 macrophages and resting CD4+ cells.
Interestingly and in agreement with our data, enrichment in mast cells
and T-lymphocytes has recently been associated not only with a more
Fig. 6. PRG4 is upregulated in high-calcified plaques and localized to ECM and activated macrophages.
(A) Volcano plot showing that PRG4 is the top significantly upregulated gene comparing all high (n= 18) vs. low (n=22) calcified plaques. (B) Bar plot shows PRG4
fold change and standard deviation among patients from microarrays. (C) By quantitative PCR from an additional non-overlapping set of patients, PRG4 showed a
non-significant trend towards upregulation in high-calcified plaques (n=5 with high calcification degree 25–34% and n=5 with low calcification 0–5%). (D) PRG4
was also strongly upregulated comparing high calcified plaques from S (n= 7) vs. AS (n=7) patients. (E) Top pathways associated with PRG4 expression in calcified
plaques microarrays. (F) Histological assessment by both immunohistochemistry and immunofluorescence confirms abundance of PRG4 in plaques, particularly in
areas positive for an early marker of calcification, osteopontin (OPN) and osteocalcin (OCN). In low calcified plaques, PRG4 (red signal) is localized in the ECM
surrounding the areas rich in both SMA+ and CD68 + cells (green signal) in the fibrous cap. In high-calcified plaques, PRG4 co-localizes with CD68+/TRAP + cells
surrounding the macro-calcified nodules (enlarged areas). Images show 1.25x (low calcified), 2x (high calcified), and enlarged images 10× magnification. Nuclear
staining with 4′,6-diamidino-2-phenylindole (DAPI). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. For interpretation of the references to color in this
figure legend, the reader is referred to the Web version of this article.)
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vulnerable plaque phenotype, but also with higher risk of adverse
cardiovascular events in patients [41,42].
We also identified numerous ECM-related genes previously not as-
sociated with atherosclerosis, such as: Proteoglycan 4 (PRG4),
Nephronectin, Dermatopontin, and Intelectin 1. Nephronectin and
Dermatopontin are recently described ECM-related genes associated
with osteoblast proliferation [43] and collagen fibrillogenesis [44],
whereas Intelectin 1 is an adipokine [45]. Interestingly, PRG4 was the
most upregulated gene associated with intimal calcification in general
and particularly in calcified plaques from S patients, but it was not
prominently enriched in association with medial calcification. Expres-
sion of PRG4 correlated with Ca-uptake and bone homeostasis genes,
and with inhibition of SMC migration, while the protein was detected
throughout the ECM and localized to SMA+ and CD68+/TRAP + cells
surrounding calcification nodules. PRG4 is a mucinous glycoprotein
secreted in joints by chondrocytes and synovial cells for boundary lu-
brication [46], recently linked with chondrogenic differentiation of
mesenchymal stem cells [47]. Expression levels of PRG4, SOX9 and
RUNX2 were positively correlated in plaques, suggesting that PRG4 is
connected to the formation of proteoglycan-rich collagenous matrix by
chondrocyte-like cells, which may also be derived from transdiffer-
entiated SMCs. Since the formation of vascular macro-calcifications has
similarities with bone remodeling [48] and PRG4 has not previously
been associated with osteolysis, the staining of PRG4 in activated
macrophages could represent protein remnants ingested after de-
gradation and remodeling processes, but the specific function of PRG4
in atherosclerotic plaque calcification remains to be determined.
With respect to limitations, the varying image acquisition protocols
used at the different admitting hospitals did not include plain CT
imaging before contrast enhancement, which may influence estimation
of plaque calcification. In addition, the resolution of CTA imaging and
the quantification software may not fully assess lesion morphology.
However, in this specific cohort, CTA-resolution should not affect the
measurements since the voxel size was<0.5mm3 and macro-
calcifications are> 1mm3. The advantage with this method is that
these tools are in routine clinical use, which may facilitate clinical
implementation. Similarly, the heterogeneous lesion composition may
not be ideally represented by the sampling protocol used in the study
that did not permit complete histological characterization of plaque
phenotype. The lack of diagnostic tools for preoperative plaque phe-
notyping preclude accurate classification of lesion stability and we have
in this study relied only on patient phenotyping with respect to clinical
symptoms. We also acknowledge that validation of gene expression
analyses obtained from microarrays was restricted as available material
from human samples did not allow for complete independent valida-
tion. Nevertheless, the presented trends were supported by analysis of a
bigger cohort and in case of PRG4, by qPCR analysis. In addition, the
obtained correlations between calcification and biological processes
were assessed in the proximal portion of the lesion while other features
(i.e. of instability) may have been more prevalent in the distal part of
the lesion that was not analysed by microarrays due to the study design.
Since BiKE comprises only late-stage carotid plaques, processes related
to disease progression could not be analysed and results are possibly not
applicable to other vascular beds. Finally, the CKD cohort consisted of
patients for living-donor transplantation, which constitute a selection of
patients with less cardiovascular disease.
In summary, using a combination of clinical patient evaluation by
CTA and plaque profiling with microarrays, we associate macro-calci-
fication in advanced carotid lesions with molecular signatures typically
linked to plaque stability, particularly related to alterations in SMC
phenotype, ECM remodeling and repression of inflammation. Similar
patterns were observed in CKD arteries with medial calcification, sug-
gesting a commonality between these two etiologies. Our study gen-
erates a resource for further mechanistic investigations of plaque cal-
cification addressing the role of specific molecular targets, such as
PRG4. From a translational aspect, this study strengthens the notion
that assessment of calcification by CTA can estimate plaque phenotype
and stroke risk, and warrants larger, prospective cohort studies to
evaluate the link between calcification and outcome in carotid patients.
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